Le Lézard
Classified in: Health
Subject: FDA

BioPlus Specialty Pharmacy Now Dispensing Newly Approved AML Cancer Medication Daurismotm


ALTAMONTE SPRINGS, Fla., Dec. 4, 2018 /PRNewswire-PRWeb/ -- BioPlus Specialty Pharmacy (BioPlus), a leading innovative specialty pharmacy, is now dispensing the limited distribution oral cancer medication Daurismotm (glasdegib) from Pfizer Inc. The U.S. Food and Drug Administration approved Daurismo on November 21, 2018. With the addition of Daurismo, BioPlus now has access to 62 limited distribution drugs, with 70% of these in the category of cancer medications.

Daurismo is an oral medication approved for the treatment of acute myeloid leukemia (AML). It will be used in combination with the chemotherapy medication cytarabine for adults age 75+ who have newly-diagnosed AML along with additional chronic health conditions that prevent the use of intensive chemotherapy. Daurismo is available to a limited distribution network of specialty pharmacies, which includes BioPlus.

Daurismo marks the fourth FDA approval for Pfizer medications in just the past two months; all of which have been limited distribution drugs. In addition, Daurismo received an Orphan Drug designation from the FDA, which is associated with incentives to assist the development of drugs for rare diseases.

"Daurismo's approval as a first-line treatment for AML offers a new treatment option for patients who cannot tolerate intensive chemotherapy," shares Sharon Ferrer, VP of Pharmaceutical Relations at BioPlus. "BioPlus is now dispensing this important new option for patients with AML. We are able to assist patients with prompt treatment starts because of our 2-Day Ready 2 Ship program that quickly gets medications to patients," she adds.

AML is a type of cancer that forms in the bone marrow and rapidly progresses. This year, according to the National Cancer Institute, 19,520 patients will be diagnosed with this form of leukemia. Of these, an estimated half of patients are not able to be treated with intensive chemotherapy due to comorbidities and chemotherapy-related toxicities.

About BioPlus Specialty Pharmacy
BioPlus Specialty Pharmacy is a leading independent, national specialty pharmacy and the first and only specialty pharmacy to offer a two-hour turnaround from referral to patient acceptance. Our company celebrates 29 years of innovative excellence in specialty pharmacy, working closely with payers and the pharmaceutical industry, as well as with prescribers to get prompt treatment for patients, and directly supporting our patients nationwide to achieve optimal health outcomes. We provide a complete range of specialty services, including for cancer, multiple sclerosis, hepatitis C, and other complex, chronic conditions. BioPlus, a privately-held, pharmacist-owned company based in Altamonte Springs, Florida, is accredited by URAC, VIPPS, and ACHC with a Distinction in Oncology.

For information: http://www.bioplusrx.com or
Contact: info(at)bioplusrx(dot)com
Phone: 1-888-292-0744

 

SOURCE BioPlus Specialty Pharmacy


These press releases may also interest you

at 13:05
Dr. J. Mark Tuthill Joins Gestalt Diagnostics' Strategic Advisory Board
Gestalt Diagnostics has added healthcare industry expert, Dr. J. Mark Tuthill, to serve on Gestalt's Advisory Board. He will be joining Gestalt's distinguished Advisory Board of pathologists contributing to oversight and active input of development...

at 12:45
Sogolytics Study Examines Patient Experience Gaps in Telehealth Adoption
Leading research and experience management firm Sogolytics has released an original study examining the telehealth landscape, highlighting its achievements and challenges in providing positive experiences for patients. "It's critical for providers...

at 12:24
West Physics Announces Acquisition of Tricord, Inc.
West Physics Consulting, LLC ("West Physics"), the leading national provider of integrated medical and health physics services, announced today that it has completed the purchase of the medical physics service division of Tricord, Inc. ("Tricord"), a...

at 12:16
Amae Health, Innovative Treatment Provider for Severe Mental Illness, Announces Closing of Oversubscribed $15 Million Series A Funding Round
Amae Health, a trailblazer in delivering patient-centered care for people with severe mental illness, announced today the successful closing of its oversubscribed $15 million Series A funding round. The round was led by Quiet Capital and included...

at 12:08
Roivios Secures FDA Breakthrough Device Designation for JuxtaFlow® RAD, Showcases Pioneering Data at Society of Cardiovascular Anesthesiologists Annual Meeting
Roivios, a pioneering clinical-stage medical device company dedicated to transforming kidney health, is thrilled to announce it has been awarded the prestigious Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its...

at 12:06
Burrell College of Osteopathic Medicine Achieves Highest Accreditation Status from AOA Commission on Osteopathic College Accreditation
Burrell College of Osteopathic Medicine (BCOM) attained the highest level of accreditation from the American Osteopathic Association (AOA) Commission on Osteopathic College Accreditation (COCA). Burrell has been awarded the prestigious accreditation...

More news about Health...


News published on and distributed by: